Sodium MR Imaging Detection of Mild Alzheimer Disease: Preliminary Study

BACKGROUND AND PURPOSE: There is significant interest in the development of novel noninvasive techniques for the diagnosis of Alzheimer disease (AD) and tracking its progression. Because MR imaging has detected alterations in sodium levels that correlate with cell death in stroke, we hypothesized that there would be alterations of sodium levels in the brains of patients with AD, related to AD cell death.

MATERIALS AND METHODS: A total of 10 volunteers (5 with mild AD and 5 healthy control subjects) were scanned with a 20-minute sodium (23Na) MR imaging protocol on a 3T clinical scanner.

RESULTS: After normalizing the signal intensity from the medial temporal lobes corresponding to the hippocampus with the ventricular signal intensity, we were able to detect a 7.5% signal intensity increase in the brains of patients with AD (AD group, 68.25% ± 3.4% vs control group, 60.75% ± 2.9%; P < .01). This signal intensity enhancement inversely correlated with hippocampal volume (AD group, 3.22 ± 0.50 cm³ vs control group, 3.91 ± 0.45 cm³; r² = 0.50).

CONCLUSIONS: This finding suggests that sodium imaging may be a clinically useful tool to detect the neuropathologic changes associated with AD.
2-tailed independent-sample t tests assuming unequal variance. All \( r^2 \) values are the square of the Pearson correlation from a bivariate correlation, unless otherwise noted.

**Subjects**

Subjects were selected from patients and cognitively normal subjects participating in the Alzheimer Disease Center (ADC) longitudinal clinical cohort. Clinical diagnosis (control and probable AD) and willingness to participate were the only selection criteria. Ten elderly volunteer participants underwent MR imaging: 5 mildly impaired patients with a clinical diagnosis of probable AD (Mini-Mental State Examination [MMSE] score: 18–28; mean, 24) and 5 age-matched healthy elderly control subjects (MMSE, 30 in all). Subjects were closely age and sex matched (control mean age, 74.4 years; SD, 5.4 years; range, 66–81 years; 4 men; AD mean age, 73.6 years; SD, 5.5 years; range, 64–77 years; 3 men). All received a standardized evaluation as specified by the National Alzheimer’s Coordinating Center (NACC). This evaluation included the collection of medical information; performance of a standardized physical and neurologic examination; and cognitive testing with the NACC Uniform Data Set psychometric battery to determine impairments in memory, language, constructional praxis, and executive function, as well as standardized ratings of mood and behavior. The degree of global impairment was assessed with the Clinical Dementia Rating. Laboratory tests (eg, blood and urine studies, MR imaging, CSF tau, beta-amyloid levels, fluorodeoxyglucose–positron-emission tomography) were done at the discretion of the evaluating clinician. The final diagnosis for each subject was established at the weekly ADC diagnostic consensus conference after presentation of all relevant data by the evaluating clinician. All subjects provided informed consent, approved by our institutional review board, to participate in this study.

**MR Imaging**

Imaging was performed with a broadband-enabled 3T Trio clinical scanner (Siemens, Erlangen, Germany). A series of scout images were first obtained in a vendor-supplied 8-channel head array coil. These were used to position an isotropic T1-weighted inversion recovery-prepared 3D gradient-recalled echo (GRE) sequence with the following parameters: FOV, 245 × 245 mm; matrix, 192 × 192; section thickness, 1.28 mm (ST); TR, 1620 ms; inversion recovery time, 950 ms; flip angle (FA), 15°; 6/8 partial Fourier (PFT) in phase encode and section encode dimensions; and scan time, 3 minutes.

The patient was then placed into a custom-built 25-cm diameter, 20-cm length, quadrature birdcage head coil with a detached radiofrequency end cap tuned to the \(^{23}\)Na resonance of 32.6 MHz. The coil was interfaced to the scanner with a custom transmit-receive switch. A low resolution, 12-second, 3-plane sodium fast GRE localizer was performed for section positioning. From this, the ventricles were clearly visible, and an outline of the head was seen to roughly position the section in the same way for each volunteer for the following coronal sodium head scan. A 0.146-cm\(^3\) voxel size, 20-minute coronal sodium spoiled fast GRE scan was then performed with the following parameters: FOV, 245 × 245 mm; matrix, 64 × 64, ST, 10 mm; TR, 9.13 ms; TE, 2.96 ms (asymmetric readout); FA, 60°; 18 sections; nonselective excitation by a 1-ms hard pulse; 6/8 PFT (phase and section); elliptical scanning, 130 Hz/Px; and averages, 210.

A B\(_1\) map was generated with an 18-cm spherical 300- mmol/L NaCl phantom by running a series of 5 fast GRE scans each with a different applied transmitter voltage to generate FAs of 50, 70, 90, 110, and 130° when averaged over the entire volume. This was performed with the same parameters as the imaging in the previous paragraph but with TR 180 ms to allow for more complete T1 recovery, and interpolated in-plane to match the images in Fig 1A. Correction on the basis of the B\(_1\) map was not necessary because of the high homogeneity in the regions of interest.

**Sodium Image Processing**

The resulting k-space was reconstructed off-line with custom written software in IDL version 6.2 (ITT Software, Boulder, Colo). K-space filtering was performed with 3 (1 for each dimension) Gaussian functions, each with an alpha of 0.5, matrix multiplied together. This was selected among numerous filter choices because it provided the highest signal-to-noise ratio without noticeable loss of image detail from the sodium images. An automated algorithm took the average of the top 10% of pixel signal intensities in the area of the brain where lateral ventricles were expected from these unsmoothed images. The pixel intensities in each section were normalized to that ventricular signal intensity and checked for each brain. Figure 1 shows representative proton and sodium images from a control subject and a patient with AD as well as coil homogeneity.

**Volume Computations**

We removed skulls and surrounding tissues from the proton isotropic images by using the Brain Extraction Tool v1.3 (http://www.fmrib.ox.ac.uk/analysis/research/bet) and checked by using 3D visualization with MRicro v1.4 (http://www.sph.sc.edu/comd/orden/microc.html). We computed total intracranial volume (TIV) by taking the total volume of all the remaining pixels, composed of brain and ventricle, from the bottom of the cerebellum to the top of the brain. We manually segmented the hippocampus using ITK-SNAP version 1.4 (http://www.itksnap.org/) according to the boundaries presented previously by Bartzokis et al by using the posterior boundary definition of Watson et al. To summarize, the most anterior section is where the alveus becomes visible, the most posterior section is the section where the crura of the fornices are seen in full profile, the lateral and inferior borders are the gray/white matter interface, the medial border is the CSF, and the subiculum and alveus are included in the measurement.

Because the sodium images offer less tissue contrast and lower resolution, the hippocampal regions obtained in the previous paragraph were used to define the areas of the hippocampus in the sodium images as follows. A rigid body co-registration was performed to match each volunteer’s proton image set to their corresponding sodium image set with use of statistical parametric mapping version 5 (SPM5, http://www.fil.ion.ucl.ac.uk/spm/). These were resectioned to match the sodium voxel size. The hippocampal volume masks underwent the same co-registration and resection as the corresponding proton images. For 1 subject, this process is displayed in Fig 2. The average sodium enhancements with use of the co-registered, resected hippocampal masks on the sodium images are then reported.

**Results**

The results of the analysis of the hippocampus-based regions of the medial temporal lobes of the control and AD cohorts are presented in the Table. Normalized overall enhancement was 60.75% ± 2.9% in the control group and 68.25% ± 3.4% in the AD group (P < .01). Hippocampal volumes, unnormalized and normalized to total intracranial volume (norm) were...
**Fig 1.** A. Representative coronal control (control C2) and AD (patient AD4) images are shown from the sections for region-of-interest analysis. The proton images demonstrate the anatomy of the brain in the corresponding sodium sections and were part of the dataset used for hippocampal volume determination. The sodium images are normalized to the ventricular signal intensity, scaled as shown with the color bar on the right, which is also used for B. The images were normalized to the brightest areas of intensity in the center of the image, seen clearly in these images as the lateral ventricles. The hippocampal volumes from the proton sets were co-registered to the sodium images and used to mask the hippocampus as described in the methods. B. Shown is the corresponding section from a $B_1$ map calculated from a spherical sodium phantom with contour lines added for each 10th percentile. This indicates excellent homogeneity over the areas of interest. The units are in $B_1$ relative to the maximum in that section scaled to the same color bar. The maximum is found at the edges of the phantom near the struts of the birdcage.

**Fig 2.** For each subject, the proton images underwent 3D co-registration and resectioning to match the sodium position for that subject and sodium voxel size. The top 3 images show from left to right: 1 section of the original proton volume, the corresponding section of the co-registered and resectioned (Morphed) proton volume, and the corresponding section of the sodium volume for that subject. The hippocampal volumes were computed from manual hippocampal masking on a section-by-section basis. The middle left image shows the hippocampal mask for the section of brain shown above. The transformation matrix obtained from the co-registration and resection of the proton volume was applied to the hippocampal mask to yield the mask in the center image for that morphed section. This was performed on a 3D basis, and the bottom line shows that transformation in 3D. The entire hippocampal volume mask is shown as a 3D rendering of the surface from a tilted superior-inferior perspective. The morphed hippocampal volume mask (bottom center) was applied to the sodium volume, and those pixels were averaged to obtain sodium enhancement.
A moderate correlation is observed overall (between sodium enhancement and unnormalized hippocampal volume, we performed a partial correlation between disease status and sodium level, controlling for the unnormalized hippocampal volumes in the correlation of sodium enhancement with diagnosis (r² = 0.53; P = .006). Sodium enhancement is taken as the average sodium enhancement of the right and left medial temporal lobes relative to ventricle. The vertical error bars represent the 95% confidence interval.

Taken from T1-weighted brain images as described in the Methods section and are presented for comparison.

Sodium MR imaging correlates more strongly with AD diagnosis (Fig 3; r² = 0.53; P = .006) than TIV normalized hippocampal volume (Fig 4; r² = 0.42; P = .034) in this preliminary study. Not shown are the correlations for the ventricular normalized sodium then normalized to TIV and diagnosis (r² = 0.24; P = .154) and unnormalized hippocampal volume and diagnosis (r² = 0.39; P = .052).

Figure 5 shows the hemisphere-to-hemisphere correlation between sodium enhancement and unnormalized hippocampal volume. A moderate correlation is observed overall (r² = 0.50; P < .01). Correlations within the control (r² = 0.24) and AD (r² = 0.24) groups were also obtained. Sodium enhancement correlated to hippocampal volume normalized to TIV demonstrates weaker correlation overall (r² = 0.27; P = .19), despite very similar pooled averages for unnormalized and normalized hippocampal volumes shown in the Table.

To test whether the sodium signal intensity differences could be explained entirely by changes in hippocampal volume, we performed a partial correlation between disease status and sodium level, controlling for the unnormalized hippocampal volumes for each hippocampus. The correlation was still significant (P = .025), indicating that the sodium detection of AD cannot be entirely explained by differences in hippocampal volume.

**Discussion**

To our knowledge, sodium MR imaging has not been previously applied to the study of AD. To provide a comparison, we computed the hippocampal volume from these subjects from proton images to provide a more thoroughly tested AD biomarker. In this novel preliminary application of sodium MR imaging, the sodium MR imaging had a higher correlation with disease state than did hippocampal volume. In the literature and in our study, normalization to TIV improved correlation with disease state for hippocampal volume. However, normalization to TIV significantly weakened the sodium imaging values, suggesting that sodium MR imaging may provide different or complementary information about disease state. In a similar fashion, the measured sodium values correlated much more with unnormalized hippocampal volumes. This finding suggests that hippocampal processes directly contribute to the observed effect. Furthermore, controlling for those hippocampal volumes in the correlation of sodium enhance-

| Patient | S | Age | RMTL | SD | LMTL | SD | RHV Norm | LHV Norm | TIV |
|---------|---|-----|------|----|------|----|----------|----------|-----|
| C1      | M | 75  | 66.6 | 9.80| 62.25| 11.8| 3.38     | 4.06     | 4.07 | 4.89 | 1330 |
| C2      | M | 76  | 64.77| 10.1| 61.04| 11.6| 3.77     | 3.59     | 3.89 | 3.71 | 1680 |
| C3      | M | 74  | 58.28| 8.12| 56.17| 10.8| 4.29     | 4.24     | 4.39 | 4.35 | 1620 |
| C4      | M | 81  | 59.30| 6.26| 59.52| 9.8 | 4.84     | 4.19     | 4.68 | 4.22 | 1770 |
| C5      | F | 66  | 61.17| 4.73| 58.41| 4.5 | 3.44     | 3.39     | 3.24 | 3.19 | 1630 |

Note: Analysis of the hippocampal signal normalized to ventricular signal is shown for 5 patients with mild AD and 5 control patients. Patient age (years) and sex (S) are indicated. RMTL indicates the right medial temporal lobe; LMTL, the left medial temporal lobe enhancement as a percentage of ventricle enhancement, an internal control; SD, for either inside that region of interest or for the entire cohort (Cohort SD). The hippocampal volumes (HV, cm³) for the right (RHV) and left (LHV) sides are shown, and next to those are the volumes normalized (Norm) to total intracranial volume (TIV, cm³). The pooled averages of the left and right averaged measurements for each subject are shown in the Average/cohort SD lines.

**Fig 3.** Compared is sodium enhancement with diagnosis (r² = 0.53; P = .006). Sodium enhancement is taken as the average sodium enhancement of the right and left medial temporal lobes relative to ventricle. The vertical error bars represent the 95% confidence interval.

**Fig 4.** Compared is diagnosis with mean hippocampal volume per subject normalized to total intracranial volume (r² = 0.42; P = .034). The vertical error bars represent the 95% confidence interval.
ment to disease state does not invalidate the observed effect. This indicates that sodium MR imaging provides additional or different information beyond measurements of hippocampal volume.

Assumptions about the physiology and composition of brain tissue help to explain the observed results. In perfused brain tissue, the concentration of extracellular sodium, $[\text{Na}]_e$, is in diffusional equilibrium with blood and CSF $[\text{Na}]$ at a constant 140 mmol/L. The concentration of intracellular sodium, $[\text{Na}]_i$, in the normal tissue is assumed to be approximately 12 mmol/L. The intracellular volume fraction ($V_i$) in gray matter is approximately 80%, whereas the extracellular volume fraction ($V_e$) is approximately 20%, and gray matter is the predominant tissue in our measured regions of interest.

In tissue sites where motional narrowing is achieved ($\omega_r\tau_e \ll 1$), sodium exhibits monoexponential transverse relaxation. Biexponential transverse relaxation is observed in tissue sites where motional narrowing is not achieved ($\omega_r\tau_e \approx 1$); the slow component of relaxation, $T_{2s}$, and fast component, $T_{2f}$, comprise 40% and 60% of the total sodium signal intensity, respectively. The static quadrupolar interaction is minor in the brain and can be effectively ignored. Averaged over the intracellular and extracellular compartments, $T_{2s}$ and $T_{2f}$, have been estimated at 15 ms and 3 ms with a proportion of 40% and 60%, respectively, for normal gray matter. This can be split further into the intracellular components $T_{2s,i}$ and $T_{2f,i}$ and extracellular components $T_{2s,e}$ and $T_{2f,e}$. The values of $T_{2s,i}$ and $T_{2f,i}$ have been approximated at their fastest from yeast cells as 7.5 and 0.35 ms, but also from rat liver as 13.0 and 1.3 ms. For extracellular fluid, $T_{2s,e}$ and $T_{2f,e}$ are thought to be significantly longer, perhaps on the order of 41.6 ms and 12.0 ms as estimated for blood serum or close to 18 ms for both components as reported for extracellular rat liver fluid. With the TE used in this study, most of the tissue sodium is visible except the component $T_{2f,i}$, making the intracellular sodium approximately 30% visible (from the $T_{2s,i}$ component, accounting for a 3-ms decay of that component), accounting for approximately 13% of the overall sodium signal intensity (for 18-ms monoexponential extracellular relaxation). The relation of all of these factors to sodium signal intensity ($S_{Na}$) is related by equation 1 where TE is the echo time of the sequence, $A$ is a constant relating to a number of additional factors including the receptivity of sodium and the system and coil electronics, and it is assumed that the intracellular and extracellular pools each have 1 correlation time.

$$S_{Na} = A \left( V_i[Na] \left( e^{-\frac{\text{TE}}{\tau_{2s,i}}} + 0.4e^{-\frac{\text{TE}}{\tau_{2f,i}}} \right) \right)$$

$$+ V_e[Na] \left( e^{-\frac{\text{TE}}{\tau_{2s,e}}} + 0.4e^{-\frac{\text{TE}}{\tau_{2f,e}}} \right)$$

Physically and physiologically reasonable changes in the parameters of the equation would cause the observed increase in sodium signal intensity. Before cell death, increased sodium in tissue could be caused by direct leakage of sodium because of amyloid beta channels in membranes or by the impairment of the Na+/K+ − ATPase. Given the large $V_i$ of brain tissue, only a modest increase in intracellular sodium would be expected to produce this change in signal intensity, even with the partial visibility of intracellular sodium of this sequence. After neuronal death, the intracellular space shrinks and the extracellular space expands, and the larger sodium concentration in the extracellular space yields a larger sodium signal intensity. This hypothesis has been put forward to explain sodium changes in studies of cerebral infarction. In addition, with cell death are changes in tissue composition, potentially increasing the transverse relaxation times in AD-affected tissue. A combination of these effects is likely, and several experiments with multiple pulse sequences would need to be performed to separate and investigate all of these parameters.

In our study, we chose a GRE sodium imaging sequence to obtain high signal-to-noise ratios (>20:1) from the regions of interest and high-image quality with minimal image blurring and good anatomic localization. Rectilinear $k$-space sampling requires a TE that produces relaxation weighting and the loss of signal intensity from some fast-relaxing sodium nuclei. Therefore, the sodium enhancement measured in our study may be the result of increases in spin attenuation, changes in sodium relaxation times, or both. Center-out $k$-space trajectories reduce relaxation weighting and capture signal intensity from the fast-relaxing sodium spins, but they increase image blurring and are more technically difficult to implement. Therefore, we believe that the rectilinear $k$-space sampling may be the optimal approach to routine clinical sodium MR imaging. As examples of the usefulness of this approach, GRE enhancement of sodium measured with even longer TE has been used to track both cerebral and myocardial infarction in animal models. Furthermore, GRE measurements of sodium have been frequently encountered in the recent literature and the sequence is easily run on any clinical scanner. It is more remarkable that even with this relatively long echo sequence, a potentially important diagnostic marker has been found.

Additional sodium studies, including on animal models of AD, can be performed to explore changes in every parameter.
in the equation to test the hypotheses put forward. Studies are currently in design to determine whether the major contribution to the signal intensity difference is because of changes in intracellular sodium concentrations, changes in the extracellular or intracellular volumes, or changes in the relaxation properties of sodium in the hippocampal areas. For example, intracellular sodium can be selected by inversion recovery or multiple-quantum filtering, and methods for total sodium measurements and relaxation mapping have been demonstrated in the literature.

Several challenges and limitations were presented in our current study. The first challenge was that any site that wishes to perform sodium imaging will need a sodium coil, scanner interface hardware, a broadband-enabled scanner capable of transmitting and receiving at sodium frequency, and a modified or custom pulse sequence for sodium. This may not be a long-term difficulty, as there is an increasing trend of availability of 3T MR imaging scanners with multinuclear capabilities. Sodium imaging fundamentally yields lower signal-to-noise ratios, and as such, higher-field clinical scanners of more than 3T are desired for their improved signal-to-noise ratio. An additional challenge was finding an appropriate standard for comparisons between subjects. Initial attempts were performed with external sodium-doped agarose reference phantoms; however, their position beside the head in close proximity to the struts of the birdcage coil caused unacceptable variations because of field inhomogeneity. To overcome this problem, we used the lateral ventricles as an internal control for sodium, as they were thought to contain a remarkably constant level of sodium very close to 140 mmol/L. In this case, it must be shown that the B1 profile of the coil is constant between the CSF and the compared tissue, or the inhomogeneity must be taken into account. To our knowledge, systematic differences in CSF sodium concentrations in neurodegeneration have not been reported.

Conclusions
Statistically significant changes in sodium signal intensity were observed between patients with mild AD and control subjects on a 3T clinical scanner. To our knowledge, this study is the first to demonstrate the feasibility of imaging AD with sodium MR. The 20-minute protocol shown here provides both good anatomic localization and signal-to-noise ratio. These sodium images can be signal intensity normalized for cohort studies, either with internal CSF/vitreous humor controls or external phantom references. A moderate inverse correlation was shown between sodium enhancement and measurements of hippocampal volume. These results demonstrate the potential of sodium MR imaging for early AD diagnosis in conjunction with anatomic proton MR imaging. We are currently exploring additional experiments with a variety of sodium pulse sequences to find the physiologic basis of these results. This would contribute to our understanding of factors responsible for the disease.

Acknowledgments
We thank Thomas J. Connick for his technical assistance with coil design and interface and Marianne Watson and Christa Nichols for their assistance with patient coordination.

References
1. Kasper DL, Harrison TR. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 2005
2. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007;69:1622–34
3. Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003;2:605–13
4. Cohen RM. The application of positron-emitting molecular imaging tracers in Alzheimer’s disease. Mol Imaging Biol 2007;9:184–16
5. Ramani A, Jensen H, Helpen JA. Quantitative MR imaging in Alzheimer disease. Radiology 2006;241:26–44
6. Seid JP, Jagust WJ, Wong ST, et al. Quantitative NMR measurements of hippocampal atrophy in Alzheimer’s disease. Magn Reson Med 1988;28:600–08
7. Jernigan TL, Salmon DP, Butters N, et al. Cerebral structure on MRI, Part II: Specific changes in Alzheimer’s and Huntington’s diseases. Biol Psychiatry 1991;29:68–81
8. Fox NC, Cousens S, Schall R, et al. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2006;57:339–44
9. Jack CR Jr, Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. Neurology 1998;5:1993–99
10. Jack CR Jr, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of miladimine for AD. Neurology 2006;63:253–60
11. Klunk WE, Panchalingam K, Moosy J, et al. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer’s disease brain: a preliminary proton nuclear magnetic resonance study. Neurology 1992;42:1578–85
12. Jessen F, Traube F, Freymann K, et al. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 2006;67:528–30
13. Falangola MF, Dyakin VV, Lee SP, et al. Quantitative MRI reveals aging-associated T2 changes in mouse models of Alzheimer’s disease. NMR Biomed 2007;20:343–51
14. El Tannir EI, Tayara N, Delatorre B, Le Cunneen C, et al. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 2006;22:199–208
15. Borthakur A, Gur T, Wheaton AJ, et al. In vivo measurement of plaque burden in a mouse model of Alzheimer’s disease. J Magn Reson Imaging 2006;24:1011–17
16. Haley AF, Knight-Scott J, Fuchs KL, et al. Shortening of hippocampal spin–spin relaxation time in probable Alzheimer’s disease: a 1H magnetic resonance spectroscopy study. Neurosci Lett 2004;362:167–70
17. Campeau NG, Petersen RC, Feldme J, et al. Hippocampal transverse relaxation time in patients with Alzheimer disease. Radiology 1997;205:197–201
18. House MI, St Pierre TG, Foster JK, et al. Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. AJNR Am J Neuroradiol 2006;27:430–39
19. Borthakur A, Wang C, Li D, et al. T1 rho MRI of patients with Alzheimer’s disease. Proceedings of the 15th Annual Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine; 2007:3727
20. Alper DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer’s disease by spin-labeled magnetic resonance imaging. Ann Neurol 2005;4:93–100
21. Lin AP, Shie F, Enriquez C, et al. Reduced glutamate neurotransmission in patients with Alzheimer’s disease – an in vivo (13)C magnetic resonance spectroscopy study. Magna 2003;16:29–42
22. Gonzalez RG, Guimaraes AR, Moore GE, et al. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10:46–52
23. Higuchi M, Iwata N, Matusoba Y, et al. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 2003;8:527–33
24. Shapiro EM, Borthakur A, Gougoutas A, et al. 23Na MRI accurately measures fixed charge density in articular cartilage. Magn Reson Med 2002;47:284–90
25. Borthakur A, Mellon E, Niyogi S, et al. Sodium and T1rho MRI for molecular and diagnostic imaging of articular cartilage. NMR Biomed 2006;19:781–821
26. Jansen MA, Van Emous JG, Nederhoff MG, et al. Assessment of myocardial viability by intracranial 23Na magnetic resonance imaging. Circulation 2004;110:3457–64
27. Turski P, et al. Houston LW, Perman WH, et al. Experimental and human brain neoplasms: detection with in vivo sodium MR imaging. Radiology 1987;163:245–49
28. Nieles-Vallespin S, Weber MA, Bock M, et al. 3D radial projection technique with ultrashort echo times for sodium MRI: clinical applications in human brain and skeletal muscle. Magn Reson Med 2007;57:74–81
29. Shimizu T, Naritomi H, Sawada T. Sequential changes on 23Na MRI after cerebral infarction. Neuroradiology 1999;35:416–19
31. Thulborn KR, Cindin TS, Davis D, et al. Comprehensive MR imaging protocol for stroke management: tissue sodium concentration as a measure of tissue viability in nonhuman primate studies and in clinical studies. Radiology 1999;213:156–66
32. Boada FE, Laverde G, Jungreis C, et al. Loss of cell ion homeostasis and cell viability in the brain: what sodium MRI can tell us. Curr Top Dev Biol 2005;76:77–101
33. Horn M. 23Na magnetic resonance imaging for the determination of myocardial viability: the status and the challenges. Curr Vasc Pharmacol 2004;2:329–33
34. Bercky DL, Ramos EM, van Belle G, et al. The National Alzheimer’s Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord 2004;10:270–77
35. Morris IC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210–16
36. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988;24:637–39
37. Alecci M, Collizu CM, Wilson J, et al. Theoretical and experimental evaluation of detached endcaps for 3 T birdcage coils. Magn Reson Med 2003;49:363–70
38. Bartzokis G, Mintz J, Marx P, et al. Reliability of in vivo volume measures of hippocampus and other brain structures using MRI. Magn Reson Imaging 1993;11:993–1006
39. Watson C, Andermann F, Gloo P, et al. Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology 1992;42:1743–50
40. Jack CR Jr, Petersen RC, O’Brien PC, et al. MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology 1992;42:183–88
41. Siegel GJ. 23Na MR imaging of sodium in the human brain with a central nervous system. AJNR 2003;10:358–65
42. Bartzokis G, Mintz J, Marx P, et al. Detection of residual quadrupolar interaction in human skeletal muscle and brain in vivo via multiple quantum fast three-dimensional gradient-recalled-echo sequence at 4 T. Acad Radiol 2003;10:358–65
43. Reddy R, Boada FE, Shen GX. Triple quantum sodium imaging of articular cartilage. Magn Reson Med 2004;52:545–51
44. Boada FE, Christensen JD, Huang-Heilinger FR, et al. Quantitative in vivo tissue sodium concentration maps: the effects of biexponential relaxation. Magn Reson Med 1994;32:219–23
45. Clayton DB, Lenkinski RE. MR imaging of sodium in the human brain with a fast three-dimensional gradient-recalled-echo sequence at 4 T. Acad Radiol 2003;10:358–65
46. Rooney WD, Springer CS, Jr. The molecular environment of intracellular sodium: 23Na NMR relaxation. NMR Biomed 1991;4:227–45
47. Bansal N, Germann MJ, Seshan V, et al. Thulium 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraakis(methylene phosphonate) as a 23Na shift reagent for the in vivo rat liver. Biochemistry 1993;32:5638–43
48. Arose N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 1993;90:567–71
49. Mark RJ, Herskens K, Butterfield DA, et al. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J Neurosci 1995;15:6239–49
50. Lin SP, Song SK, Miller JP, et al. Direct, longitudinal comparison of (1)H and (23)Na MRI after transient focal cerebral ischemia. Stroke 2001;32:925–32
51. Kim RJ, Judd RM, Chen EL, et al. Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. Circulation 1999;100:185–92
52. Alecci M, Romanzetti S, Kallfanke I, et al. Practical design of a 4 Tesla double-tuned RF surface coil for interleaved 1H and 23Na MRI of rat brain. J Magn Reson 2006;181:203–11
53. Bartha R, Menon RS. Long component time constant of 23Na T2 relaxation in healthy human brain. Magn Reson Med 2004;52:407–10
54. Steidle G, Graf H, Schick F. Sodium 3-D MRI of the human torso using a volume coil. Magn Reson Imaging 2004;22:171–80
55. Sandstede JJ, Hillenbrand H, Beer M, et al. Time course of 23Na signal intensity after myocardial infarction in humans. Magn Reson Med 2004;52:545–51
56. Reddy R, Insko EK, Leigh JS. Triple quantum sodium imaging of articular cartilage. Magn Reson Med 1997;38:279–84
57. Hancu I, Boada FE, Shen GX. Three-dimensional triple-quantum-filtered (23)Na imaging of in vivo human brain. Magn Reson Med 1999;42:1146–54
58. Borthakur A, Hancu I, Boada FE, et al. In vivo triple quantum filtered twisted projection sodium MRI of human articular cartilage. J Magn Reson 1999;141:286–90
59. Ouwerkerk R, Bleich KB, Gillen JS, et al. Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology 2003;227:529–37